

## **Appendix 4E**

### **Preliminary Final Report**

#### **1. Company Details**

Name of Entity

<b>Oneview Healthcare PLC</b>
-------------------------------

ABN or equivalent  
reference

**610 611 768**

Financial year ended  
(current period)

**31 December 2017**

Financial year ended company  
(previous period)

**31 December 2016**

#### **2. Results for announcement to the market**

	<b>Up/down</b>	<b>% change</b>	<b>31 December 2017 €'000</b>	<b>31 December 2016 €'000</b>
Recurring revenue from ordinary activities	Up	66%	2,546	1,531
Total revenue from ordinary activities	Down	30%	6,313	9,028
(Loss) from ordinary activities after tax attributable to members (including significant items)	Down	62%	(25,901)	(16,030)
(Loss) from ordinary activities after tax attributable to members (excluding significant items *)	Down	43%	(21,996)	(15,385)

\* Significant items incurred include FX and non-cash share based payments (2016: IPO related costs, FX and non-cash share based payments).

#### **3. Dividends**

The Company has not declared, and does not propose to pay, any dividends for the year ended 31 December 2017 (31 December 2016: Nil). There are no dividend or dividend reinvestment plans in operation.

#### **4. Brief explanation of any of the figures reported above necessary to enable the figures to be understood**

The principal activity of the Group is the development and sale of software for the healthcare sector and the provision of related consultancy services.

The directors report that revenue for the year from continuing operations amounted to €6,312,713 (2016: €9,028,422), a decrease of 30%. Recurring revenue for the year amounted to €2,546,104 (2016: €1,531,078), an increase of 66% and continues to grow as the company deploys incrementally across its increasing customer base. New sales of the Company's Inpatient solution in the crucial North American market were negatively impacted by procurement inertia following the change of administration in Washington in January 2017.

During the year, the company began implementations across a number of new North American customers including Lancaster General Hospital, Barnes Jewish Hospital, NYU Langone, St. Louis Children's Hospital and University Hospitals of Cleveland. In Australia, the company deployed its Oneview Connect application at the Sydney Children's Hospital Network. We finished the year with over 50 hospitals contracted globally of which 28 are currently live and leveraging the power of the Oneview platform for their patients on a daily basis.

In the UK, the company completed a highly successful pilot program for prostate cancer pathways with The University of Oxford and Oxford University Hospitals NHS Foundation Trust, which culminated in the signing of a 5-year R&D agreement in December 2017 to expand the pathways program to cancers other than prostate cancer.

As at 31 December 2017, the Oneview Inpatient solution was live in 3,582 beds with a further 5,416 beds contracted but not yet installed. The Company expects the majority of these contracted beds to be installed during the 2018 calendar year. There were a further 4,923 beds in contract negotiation and 12,990 in tender process. During the year, Oneview announced its inaugural contract success for the Connect application in the United States at the high-profile St. Jude Children's Research Hospital in Memphis, Tennessee. Subsequent to year-end, the Company announced on a number of further contract successes including the signing of a contract with Mater Misericordiae Limited, for 904 beds across 9 facilities in Queensland, Australia. We also announced a six-year contract extension with Chris O'Brien Lifehouse in Sydney, our first Australian customer and a great endorsement of our partnership with this world-renowned cancer centre. Finally, we announced the continued expansion of our relationship with the University of California San Francisco with the expansion to the UCSF Benioff Children's Hospital Oakland and UCSF Parnassus, reporting an additional 330 devices. The Company continues to grow its pipeline of new business opportunities in all of its key target markets.

The business has continued to invest in world-class talent across each of its primary office locations and increased the headcount by 7% to 162 staff as at 31 December 2017 (151 at 31 December 2016). The growth in headcount has been primarily in the areas of sales, implementation and research and development.

For further information, please refer to the attached Annual Report for the Year ended 31 December 2017.

**5. Statement of Comprehensive Income**

Please refer to the Statement of Comprehensive Income in the attached Annual Report.

**6. Statement of Financial position**

Please refer to the Statement of Financial Position in the attached Annual Report.

**7. Statement of Cash Flows**

Please refer to the Statement of Cash Flows in the attached Annual Report.

**8. Statement of Retained Earnings**

Please refer to the Statement of Changes in Equity in the attached Annual Report.

**9. Net Tangible Assets Per Security**

	<b>31 December 2017</b>	<b>31 December 2016</b>
	<b>€</b>	<b>€</b>
Net Tangible Assets Per Security	0.42	0.65

Net tangible assets are defined as the net assets of Oneview Healthcare Plc less intangible assets. A small proportion of the Company's assets are intangible in nature. These assets are excluded from the calculation of net tangible assets per security shown above.

On 29 November 2017, the Company completed an institutional offer issuing 10,877,705 new shares of €0.001 each at a price per share of A\$2.00. On 11 December 2017 the Company completed a retail offer issuing 4,127,818 new shares of €0.001 each at a price per share of A\$2.00. The net proceeds of the combined offerings were €17.8m. after costs of €1.39m associated with the fund raising which has been offset against retained earnings. The directors intend to utilise the proceeds to provide balance sheet flexibility to deliver on the Company's growth strategy.

**10. Details of entities over which control has been gained or lost during the period**

There are no entities over which control has been gained or lost in the period

**11. Associates and joint venture entities**

There are no associate or joint venture entities

**12. Foreign entity accounting standards**

The Financial Statements contained within the Annual Report are prepared in accordance with International Financial Reporting Standards

**13. Audit Statement**

The Annual Report has been audited by KPMG and an unqualified audit report issued.



John Kelly  
Chief Financial Officer

Date: 26 February 2018